Nicofuranose
Chemical compound
- C10AD03 (WHO)
- 1,3,4,6-tetrakis-O-(pyridin-3-ylcarbonyl)-β-D-fructofuranose
- 15351-13-0
- 25495
- 23791
N
- GF99P6327K
- D07189
Y
- DTXSID6023365
- Interactive image
- C1=CC(=CN=C1)C(=O)OC[C@@H]2[C@H]([C@@H]([C@](O2)(COC(=O)C3=CN=CC=C3)O)OC(=O)C4=CN=CC=C4)OC(=O)C5=CN=CC=C5
InChI
- InChI=1S/C30H24N4O10/c35-26(19-5-1-9-31-13-19)40-17-23-24(42-28(37)21-7-3-11-33-15-21)25(43-29(38)22-8-4-12-34-16-22)30(39,44-23)18-41-27(36)20-6-2-10-32-14-20/h1-16,23-25,39H,17-18H2/t23-,24-,25+,30-/m1/s1N
- Key:FUWFSXZKBMCSKF-ZASNTINBSA-NN
N
Y (what is this?) (verify)Nicofuranose is a niacin derivative used as a hypolipidemic agent.[1]
References
- ^ Kopelevich VM, Gunar VI (1999). "Some approaches to the directed search for new drugs based on nicotinic acid". Pharm Chem J. 33 (4): 177–187. doi:10.1007/BF02509934.
- v
- t
- e
Lipid-lowering agents (C10)
| Cholesterol absorption inhibitors, NPC1L1 |
|
|---|---|
| Bile acid sequestrants/resins (LDL) |
| Statins (HMG-CoA reductase, LDL) | |
|---|---|
| Niacin and derivatives (HDL and LDL) |
|
| MTTP inhibitors (VLDL) | |
| ATP citrate lyase inhibitors (LDL) | |
| Thyromimetics (VLDL) |
| PPAR agonists (LDL) |
| ||||
|---|---|---|---|---|---|
| CETP inhibitors (HDL) | |||||
| PCSK9 inhibitors (LDL) | |||||
| ANGPTL3 inhibitors (LDL/HDL) |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
